Figure 7. Tumor free survival in K14E6/E7 mice.
K14E6/E7 mice were given no treatment (Control), topical BEZ235 alone (topical BEZ235), DMBA alone (DMBA), or DMBA and topical BEZ235 concurrently (DMBA+ topical BEZ235). Mice were evaluated weekly, then euthanized at 20 weeks. The DMBA+BEZ235 group survived, on average, 19.3 weeks prior to tumor onset, whereas the DMBA alone group survived, on average, 16.9 weeks. This difference in tumor free survival was significant at P < 0.000001.